Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA

Cancer Science

Volumn 97, Issue 10, 2006, Pages 1082-1092

  Cho, Nam Hoon ^a   Choi, Yoon Pyo ^a   Moon, Dong Suk ^b   Kim, Haeryoung ^a   Kang, Suki ^a   Ding, Owen ^a   Rha, Sun Young ^a   Yang, Yeon Ju ^a   Cho, Sang Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Department of Chest Surgery   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN A1; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE S PHASE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; UPREGULATION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL PROLIFERATION; CYCLIN A; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 33748288083     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00292.x     Document Type: Article

References (40)

1. Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E, Murray GI. Gene expression profiling in non-small cell lung cancer: From molecular mechanisms to clinical application. Clin Cancer Res 2004; 10: 3237-48.
2. Ferreira CG, Huisman C, Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002; 41: 57-77.
3. Bunn PA Jr, Shepherd FA, Sandler A et al. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer 2003; 41 (Suppl. 1): S175-86.
4. Nemunaitis J, Swisher SG, Timmons T et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J Clin Oncol 2000; 18: 609-22.
5. Wadler S. Perspectives for cancer therapies with cdk2 inhibitors. Drug Resist Updat 2001; 4: 347-67.
6. Tuschl T. RNA interference and small interfering RNAs. Chembiochem 2001; 2: 239-45.
7. Castanotto D, Li H, Rossi JJ. Functional siRNA expression from transfected PCR products. RNA 2002; 8: 1454-60.
8. Novina CD, Sharp PA. The RNAi revolution. Nature 2004; 430: 161-4.
9. Silva J, Chang K, Hannon G, Rivas F. RNA-interference-based functional genomics in mammalian cells: Reverse genetics coming of age. Oncogene 2004; 23: 8401-9.
10. Semizarov D, Kroeger P, Fesik S. siRNA-mediated gene silencing: A global genome view. Nucleic Acids Res 2004; 32: 3836-45.
11. Ichim TE, Li M, Qian H et al. RNA interference: A potent tool for gene specific therapeutics. Am J Transplantation 2004; 4: 1227-36.
12. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-94.
13. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1991; 11: 961-71.
14. Yang R, Morosetti R, Koeffler HP. Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res 1997; 57: 913-20.
15. Sweeney C, Murphy M, Kubelka M et al. A distinct cyclin A is expressed in germ cells in the mouse. Development 1996; 122: 53-64.
16. Howe JA, Howell M, Hunt T, Newport JW. Identification of a developmental timer regulating the stability of embryonic cyclin A and a new somatic A-type cyclin at gastrulation. Genes Dev 1995; 9: 1164-76.
17. Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica-Worms H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol 1994; 14: 8420-31.
18. Porter LA, Singh G, Lee JM. Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis. Blood 2000; 95: 2645-50.
19. Moore JD, Kirk JA, Hunt T. Unmasking the S-phase-promoting potential of cyclin B1. Science 2003; 300: 987-90.
20. Pan ZQ, Amin A, Hurwitze J. Characterization of the in vitro reconstituted cyclin A or B1-dependent CDK2 and Cdc2 kinase activities. J Biol Chem 1993; 268: 20443-51.
21. Sarafan-Vasseur N, Lamy A, Bourguignon J et al. Overexpression of B-type cyclins alters chromosomal segregation. Oncogene 2002; 2: 2051-7.
22. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: A molecular definition. Oncogene 2004; 23: 2825-37.
23. Yin XY, Grove L, Datta NS, Katula K, Long MW, Prochownik EV. Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res 2001; 61: 6487-93.
24. Kim TM, Jeong HJ, Seo MY et al. Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. Clin Cancer Res 2005; 11: 79-86.
25. Yang YH, Dudoit S, Luu P et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002:30: e15.
26. Motokura T, Arnold A. Cyclins and oncogenesis. Biochim Biophys Acta 1993; 1155: 63-78.
27. Ivanchuk SA, Rutka JT. The cell cycle: Accelerators, brakes and checkpoints. Neurosurgery 2004; 54: 692-700.
28. Doree M, Galas S. The cyclin-dependent protein kinases and the control of cell division. FASEB J 1994; 8: 1114-21.
29. Luciani MG, Hutchins JR, Zheleva D, Hupp TR. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol 2000; 300: 503-18.
30. Lukas C, Sorensen CS, Kramer E et al. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 1999; 401: 815-8.
31. Fan G, Ma X, Wong PY, Rodrigues CM, Steer CJ. p53 dephosphorylation and p21 (Cip1/Waf1) translocation correlate with caspase-3 activation in TGF-β1-induced apoptosis of HuH-7 cells. Apoptosis 2004; 9: 211-21.
32. Wang Y, Prives C. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 1995; 376: 88-91.
33. Zhen W, Lijun W, Linhao L, Shinichi T, Satoshi O, Takashi I. P53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J Pharmacol Sci 2004; 94: 166-76.
34. Rangnekar VM. Apoptosis mediated by a novel leucine zipper protein Par-4. Apoptosis 1998; 3: 61-6.
35. Park SE, Choi HJ, Yee SB et al. Synthetic bile acid derivatives inhibit cell proliferation and induce apoptosis in HT-29 human colon cancer cells. Int J Oncol 2004; 25: 231-6.
36. Shao RG, Shimizu T, Pommier Y. Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. Exp Cell Res 1996; 227: 190-6.
37. Shibata Y, Nishimura S, Okuyama A, Nakamura T. p53-independent induction of apoptosis by cyclin-dependent kinase inhibition. Cell Growth Differ 1996; 7: 887-91.
38. Zapata JM, Pawlowski K, Haas E, Ware CF, Godzik A, Reed JC. A diverse family of proteins containing tumor necrosis factor receptor associated factor domains. J Biol Chem 2001; 276: 24242-52.
39. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92: 212-6.
40. Kim EH, Kim SU, Choi KS. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005; 24: 838-49.